Beam Therapeutics Inc. Reports Q2 2026 Financial Results

What Happened
Beam Therapeutics Inc. announced its financial results for the quarter ended June 30, 2026 and filed an 8-K on August 4, 2026 to furnish the company press release. The press release reporting the quarterly results is included as Exhibit 99.1 and is incorporated by reference in the filing. The report was signed by CEO John Evans on August 4, 2026.

Key Details

• Filing date: August 4, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Period covered: quarter ended June 30, 2026 (Q2 2026).
• Exhibit furnished: Exhibit 99.1 — press release announcing the company’s quarterly financial results.
• Administrative exhibits: Exhibit 104 (Cover Page Interactive Data File / Inline XBRL).
• Form signed by: John Evans, Chief Executive Officer (dated Aug 4, 2026).

Why It Matters
This 8‑K is a timely disclosure that the company has released its quarterly earnings and related financial information; investors should review the furnished press release for revenue, profit/loss, cash position and any updated guidance or operational highlights. Because the filing only furnishes the press release (and does not itself restate specific financial figures), retail investors should read Exhibit 99.1 to get the detailed metrics that could affect BEAM’s stock valuation and near‑term outlook.